Clinical trial NCT01234311: A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Prostate Cancer
Lead sponsor: Active Biotech AB
Sponsor class: INDUSTRY
First posted: 2010-11-04
Enrollment: 1245
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase 3 randomized, double blind, placebo controlled study of tasquinimod in asymptomatic to mildly symptomatic patients with metastatic CRPC to confirm the effect of tasquinimod on delaying disease progression compared with placebo.

Approximately 1200 eligible patients with metastatic CRPC will be randomly assigned in a 2:1 ratio to 1 of 2 treatment groups: Treatment Group A (tasquinimod 0.25, 0.5, or 1 mg/day; n=800) or Treatment Group B (placebo; n=400).

Detailed description: This is a Phase 3 randomized, double blind, placebo controlled study of tasquinimod in asymptomatic to mildly symptomatic patients with metastatic CRPC to confirm the effect of tasquinimod on delaying disease progression compared with placebo.

Approximately 1200 eligible patients with metastatic CRPC will be randomly assigned in a 2:1 ratio to 1 of 2 treatment groups: Treatment Group A (tasquinimod 0.25, 0.5, or 1 mg/day; n=800) or Treatment Group B (placebo; n=400).

Eligibility criteria: Inclusion Criteria:

1. Age at least 18 years at the time of signing the informed consent form. For patients in Taiwan the minimum age is 20 years.
2. Histologically confirmed diagnosis of adenocarcinoma of the prostate.
3. Evidence of bone metastatic disease on radiographic examination, whether from bone scan or other imaging modality.
4. Castrate levels of serum testosterone (≤50 ng/dL or 1.7 nmol/L).
5. Evidence of progressive disease.
6. Karnofsky score ≥70%.
7. Meet screening laboratory values as specified in thr protocol.
8. If sexually active with partner of childbearing potential, patient will agree to use adequate contraceptive methods (barrier contraceptive with spermicide or vasectomy) while on study drug. The adequate contraceptive method should be continued for 14 days after the patient stops taking study drug.
9. No evidence (within 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).
10. Able to swallow and retain oral medication.
11. Able to adhere to the study visit schedule and other protocol requirements.
12. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study.
13. Able (or patient's legal guardian, if applicable) to sign and date the written informed consent after being informed of the full nature and purpose of the study, including possible risks and side effects, and given ample time and opportunity to read and understand this information.

Exclusion Criteria:

1. Prior cytotoxic chemotherapy for the treatment of prostate ca within 2 years or within 4 weeks for Estracyt (estramustine) prior to study treatment.
2. Previous anticancer therapy using radiation, biologics or vaccines, including abiraterone, TAK-700 (Orteronel), or MDV3100 within 4 weeks prior or sipuleucel-T (Provenge) within 2 weeks prior to the start of study treatment. If radiation therapy is applied after baseline scan, a new baseline scan needs to be done at least 4 weeks after the radiation therapy.
3. Previous therapy with antiandrogens within 4 weeks (within 6 weeks for bicalutamide eg, Casodex®) prior to study treatment.
4. Concurrent use of other anticancer agents or treatments, with the following exceptions:

   • Ongoing treatment with luteinizing hormone-releasing hormone agonists or antagonists, denosumab (Prolia) or bisphosphonate (eg, zoledronic acid) is allowed. Ongoing treatment should be kept at a stable schedule; however, if medically required, a change of dose, compound, or both is allowed.
5. Any treatment modalities involving major surgery within 4 weeks prior to the start of study treatment.
6. Prostate ca pain that requires ongoing treatment with narcotic analgesics or warrants the initiation of radio- or chemotherapy.
7. Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4 (Section 4.6.8.1).
8. Maintenance treatment with corticosteroids corresponding to a prednisolone or prednisone dose above 10 mg/day. The dose must have been stable for at least 5 days.
9. Systemic exposure to ketoconazole or other strong cytochrome P450 (CYP) 3A4 isozyme inhibitors or inducers within 14 days prior to the start of study treatment. Systemic exposure to amiodarone is not allowed within 1 year prior to the start of study treatment.
10. Ongoing treatment with sensitive CYP1A2 substrate or CYP1A2 substrate with narrow therapeutic range at the start of study treatment.
11. Ongoing treatment with CYP3A4 substrate with narrow therapeutic range at the start of study treatment.
12. Simultaneous participation in any other study involving treatment with investigational drugs or having received treatment with investigational drugs less than 4 weeks prior to the start of study treatment.
13. Myocardial infarction, percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass graft, class III/IV congestive heart failure, cerebrovascular accident, transient ischemic attack, or limb claudication at rest, within 6 months prior to start of study treatment and ongoing symptomatic dysrhythmias, unstable angina, uncontrolled hypertension, and uncontrolled atrial or ventricular arrhythmias.
14. History of pancreatitis.
15. Known brain or epidural metastases.
16. Known positive serology for HIV (patients with known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in an immunocompromised host).
17. Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of a chronic viral hepatitis or known viral hepatitis carrier (patients who have recovered from hepatitis will be allowed to enter the study).
18. Patients with active tuberculosis (TB), or with known, untreated latent TB. (Country-specific TB therapy should have been given for at least 30 days prior to the start of study treatment and the patient should intend to complete the entire course of that therapy.)
19. Any condition, including other active or latent infections, medical or psychiatric conditions, or the presence of laboratory abnormalities, which could confound the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study.
20. Any patient who in the opinion of the investigator should not participate

Primary outcomes:
measure: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
state: Arizona
city: Oxnard
country: United States
state: California
city: Santa Monica
country: United States
state: California
city: Santa Rosa
country: United States
state: California
city: Wellington
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Meridian
country: United States
state: Idaho
city: Melrose Park
country: United States
state: Illinois
city: Park Ridge
country: United States
state: Illinois
city: Jeffersonville
country: United States
state: Indiana
city: Baltimore
country: United States
state: Maryland
city: Rockville
country: United States
state: Maryland
city: Boston
country: United States
state: Massachusetts
city: Jefferson City
country: United States
state: Missouri
city: Las Vegas
country: United States
state: Nevada
city: Hackensack
country: United States
state: New Jersey
city: Lawrenceville
country: United States
state: New Jersey
city: Buffalo
country: United States
state: New York
city: Poughkeepsie
country: United States
state: New York
city: Concord
country: United States
state: North Carolina
city: Durham
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Springfield
country: United States
state: Oregon
city: Bala Cynwyd
country: United States
state: Pennsylvania
city: Lancaster
country: United States
state: Pennsylvania
city: Pittsburgh
country: United States
state: Pennsylvania
city: Myrtle Beach
country: United States
state: South Carolina
city: Nashville
country: United States
state: Tennessee
city: Dallas
country: United States
state: Texas
city: Salt Lake
country: United States
state: Utah
city: Fairfax
country: United States
state: Virginia
city: Norfolk
country: United States
state: Virginia
city: Salem
country: United States
state: Virginia
city: Burien
country: United States
state: Washington
city: Ciudad Autonoma de Buenos Aires
country: Argentina
city: Santa Rosa
country: Argentina
city: Venado Tuerto
country: Argentina
city: Camperdown
country: Australia
state: New South Wales
city: Coffs Harbour
country: Australia
state: New South Wales
city: Darlinghurst
country: Australia
state: New South Wales
city: Tweed Heads
country: Australia
state: New South Wales
city: Richmond
country: Australia
state: Victoria
city: Subiaco
country: Australia
state: Western Australia
city: Bruxelles
country: Belgium
city: Gent
country: Belgium
city: Kortrijk
country: Belgium
city: Liege
country: Belgium
city: Botucatu, Sao Paulo
country: Brazil
city: Cachoeiro de Itapemirim - ES
country: Brazil
city: Curitiba, Parana
country: Brazil
city: Florianopolis
country: Brazil
city: Juiz de Fora, Minas Gerais
country: Brazil
city: Mogi das Cruzes, Sao Paulo
country: Brazil
city: Natal, Rio Grande do Norte
country: Brazil
city: Passo Fundo
country: Brazil
city: Porto Alegre, RS
country: Brazil
city: Rio de Janeiro
country: Brazil
city: Salvador/BA
country: Brazil
city: Sao Paulo
country: Brazil
city: Volta Redonda - RJ
country: Brazil
city: Pleven
country: Bulgaria
city: Plovdiv
country: Bulgaria
city: Sofia
country: Bulgaria
city: Varna
country: Bulgaria
city: Kelowna
country: Canada
state: British Columbia
city: Victoria
country: Canada
state: British Columbia
city: Brantford
country: Canada
state: Ontario
city: North York
country: Canada
state: Ontario
city: Oakville
country: Canada
state: Ontario
city: Santiago
country: Chile
city: Temuco
country: Chile
city: Vina del Mar
country: Chile
city: Beijing
country: China
city: Chengdu
country: China
city: Shanghai
country: China
city: Shantou
country: China
city: Wuhan
country: China
city: Bogota
country: Colombia
city: Cali
country: Colombia
city: Novy Jicin
country: Czech Republic
city: Olomouc
country: Czech Republic
city: Praha 2
country: Czech Republic
city: Praha 5
country: Czech Republic
city: Usti nad Labem
country: Czech Republic
city: Tartu
country: Estonia
city: Angers
country: France
city: Cannes
country: France
city: Marseille
country: France
city: Montpellier
country: France
city: Paris
country: France
city: Pierre Benite
country: France
city: Rennes
country: France
city: Suresnes
country: France
city: Dresden
country: Germany
city: Hamburg
country: Germany
city: Koln
country: Germany
city: Mannheim
country: Germany
city: Marburg
country: Germany
city: Munchen
country: Germany
city: Munster
country: Germany
city: Nurtingen
country: Germany
city: Tubingen
country: Germany
city: Weiden
country: Germany
city: Athens
country: Greece
city: Patras
country: Greece
city: Thessaloniki
country: Greece
city: Pune
country: India
city: Beer-Sheva
country: Israel
city: Haifa
country: Israel
city: Jerusalem
country: Israel
city: Petach Tikva
country: Israel
city: Ramat-Gan
country: Israel
city: Tel-Aviv
country: Israel
city: Zerifin
country: Israel
city: Cremona
country: Italy
city: Lecco
country: Italy
city: Meldola
country: Italy
city: Milano
country: Italy
city: Padova
country: Italy
city: Ravenna
country: Italy
city: Roma
country: Italy
city: Torino
country: Italy
city: Gwangju
country: Korea, Republic of
city: Seoul
country: Korea, Republic of
city: Liepaja
country: Latvia
city: Riga
country: Latvia
city: Beirut
country: Lebanon
city: Bsalim
country: Lebanon
city: Kaunas
country: Lithuania
city: Vilnius
country: Lithuania
city: Chihuahua, Chih.
country: Mexico
city: Culiacan, Sinaloa
country: Mexico
city: Leon, GTO
country: Mexico
city: Puebla
country: Mexico
city: Zapopan, Jalisco
country: Mexico
city: Amsterdam
country: Netherlands
city: Groningen
country: Netherlands
city: Leiden
country: Netherlands
city: Nijmegen
country: Netherlands
city: Tilburg
country: Netherlands
city: Christchurch
country: New Zealand
city: Nelson
country: New Zealand
city: Palmerston North
country: New Zealand
city: Tauranga
country: New Zealand
city: Panama
country: Panama
city: Arequipa
country: Peru
city: Bialystok
country: Poland
city: Lodz
country: Poland
city: Myslowice
country: Poland
city: Poznan
country: Poland
city: Warszawa
country: Poland
city: Wroclaw
country: Poland
city: Baia Mare
country: Romania
city: Bucharest
country: Romania
city: Cluj-Napoca
country: Romania
city: Craiova
country: Romania
city: Ploiesti
country: Romania
city: Suceava
country: Romania
city: Timisoara
country: Romania
city: Ekaterinburg
country: Russian Federation
city: Moscow
country: Russian Federation
city: Novosibirsk
country: Russian Federation
city: Omsk
country: Russian Federation
city: St. Petersburg
country: Russian Federation
city: Vladimir
country: Russian Federation
city: Bratislava
country: Slovakia
city: Trencin
country: Slovakia
city: Sevilla
country: Spain
state: Andalucia
city: Zaragoza
country: Spain
state: Aragon
city: Oviedo
country: Spain
state: Asturias
city: Santander
country: Spain
state: Cantabria
city: Sabadell
country: Spain
state: Cataluna
city: Alcorcon
country: Spain
state: Madrid, Communidad de
city: Pamplona
country: Spain
state: Navarra
city: Barcelona
country: Spain
city: San Sebastian de los Reyes
country: Spain
city: Valencia
country: Spain
city: Göteborg
country: Sweden
city: Karlstad
country: Sweden
city: Stockholm
country: Sweden
city: Kaohsiung
country: Taiwan
city: Taichung
country: Taiwan
city: Taipei
country: Taiwan
city: Taoyuan
country: Taiwan
city: Istanbul
country: Turkey
city: Chernivtsi
country: Ukraine
city: Dnipropetrovsk
country: Ukraine
city: Donetsk
country: Ukraine
city: Ivano-Frankivsk
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kyiv
country: Ukraine
city: Lutsk
country: Ukraine
city: Lviv
country: Ukraine
city: Odesa
country: Ukraine
city: Uzhgorod
country: Ukraine
city: Zaporizhzhya
country: Ukraine
city: Birmingham
country: United Kingdom
city: Chichester
country: United Kingdom
city: Leeds
country: United Kingdom
city: London
country: United Kingdom
city: Northwood
country: United Kingdom
city: Nottingham
country: United Kingdom
city: Oxford
country: United Kingdom
city: Scunthorpe
country: United Kingdom
city: Sutton
country: United Kingdom
Study officials:
affiliation: Johns Hopkins Kimmel Cancer Center, Baltimore, MD
name: Michael A Carducci, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle O, Carducci MA, Morris MJ. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093.
citation: Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bogemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13.